Back to top
more

Akebia Therapeutics (AKBA)

(Real Time Quote from BATS)

$1.42 USD

1.42
3,351,102

+0.11 (8.40%)

Updated Jul 16, 2024 03:55 PM ET

After-Market: $1.42 0.00 (0.00%) 4:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (162 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

    by Zacks Equity Research

    Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

      Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

      by Zacks Equity Research

      Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.

        Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

        by Zacks Equity Research

        Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

          Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

          by Zacks Equity Research

          Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

            Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

            by Zacks Equity Research

            Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

              GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%

              by Zacks Equity Research

              GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.

                BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

                by Zacks Equity Research

                The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

                  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

                  by Zacks Equity Research

                  GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

                    Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

                    by Zacks Equity Research

                    Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

                      BioMarin Presents Interim Data on BMN 250 from Phase I/II

                      by Zacks Equity Research

                      BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

                        Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

                        by Zacks Equity Research

                        Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

                          FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

                          by Zacks Equity Research

                          Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

                            Strength Seen in Catalent (CTLT): Stock Soars 13.9%

                            by Zacks Equity Research

                            Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

                              Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

                              by Zacks Equity Research

                              Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

                                KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%

                                by Zacks Equity Research

                                KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.

                                  Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%

                                  by Zacks Equity Research

                                  Advanced Accelerator Applications S.A. (AAAP) moved big last session, as its shares rose over 5% on the day.

                                    Concordia International (CXRX) Looks Good: Stock Jumps 11.4%

                                    by Zacks Equity Research

                                    Concordia International Corp. (CXRX) shares rose over 11% in the last trading session.

                                      Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

                                      by Zacks Equity Research

                                      Akebia Therapeutics (AKBA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.

                                        Moving Average Crossover Alert: Akebia (AKBA)

                                        by Zacks Equity Research

                                        Akebia Therapeutics, Inc. (AKBA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

                                          Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session

                                          by Zacks Equity Research

                                          Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

                                            Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?

                                            by Zacks Equity Research

                                            Akebia Therapeutics (AKBA) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.

                                              Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist

                                              by Zacks Equity Research

                                              On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).

                                                Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue?

                                                by Zacks Equity Research

                                                As of late, it has definitely been a great time to be an investor in Akebia Therapeutics Inc (AKBA).

                                                  Tirthankar Chakraborty headshot

                                                  New Strong Buy Stocks for December 28th

                                                  by Tirthankar Chakraborty

                                                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday